TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00618072

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin and rosiglitazone
Description: 4 week dosage escalation of metformin, 500 mg/day (or placebo) to a total dose of 2000mg/day; starting dose of rosiglitazone 2mg/day(or placebo) added at weeks 3 and weeks 4 to a a total dose of 4 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin and rosiglitazone
Description: 4 week dosage escalation of metformin, 500 mg/day (or placebo) to a total dose of 2000mg/day; starting dose of rosiglitazone 2mg/day(or placebo) added at weeks 3 and weeks 4 to a a total dose of 4 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin and rosiglitazone
Description: 4 week dosage escalation of metformin, 500 mg/day (or placebo) to a total dose of 2000mg/day; starting dose of rosiglitazone 2mg/day(or placebo) added at weeks 3 and weeks 4 to a a total dose of 4 mg/day
Study: NCT01975753

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Study: NCT04229082

Intervention type: OTHER
Intervention: observational

Intervention type: OTHER
Intervention: observational
Study: NCT04048876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90001
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT01578525

Intervention type: OTHER
Group type: OTHER
Intervention: Pharmaceutical Care Service
Description: Checking medication under safety considerations (medication at admission, hospitalization, discharge); recommendations for potentially inappropriate medication (PRISCUS-criteria),
Study: NCT01975753

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Study: NCT04479423

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soda-water instead of pure water to observe gastric filling
Description: All patients underwent a bowel preparation that consisted of a low-residue diet for 24 hours, fluid intake, and ingestion of 2L polyethylene glycol-based electrolyte solution 12 hours before the examination. On the examination day, patients arrived at hospital in the morning after an over night fast (\>8hours). Then they would be randomly assigned to controll group or soda group. 40 minutes before capsule ingestion, all patients swallowed 100ml clear water containing 50mg simethicone. During the period, patients were asked to have a proper walk to wash out bubbles. An additional 900ml pure water or 400ml soda-water was drunk to obtain good vision before undergoing MCE examination.
Study: NCT03087669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LVAD flow velocity setting-Rounds per Minute(RPM) on HeartMate III®
Description: Increase in LVAD RPM setting induces an actual increase in LVAD outflow to the patient.This gives the patient an increased systemic Cardiac Output(CO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAP intervention using Noradrenalin
Description: At a fixed RPM rate for the LVAD the Mean Arterial Pressure (MAP) is increased to preset levels of 60-70-80-90 mmHG using Noradrenalin
Study: NCT00333814

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 350 µg; injection drug delivery system at Day 0

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Dexamethasone 700 µg injection drug delivery system at Day 0

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Sham injection at Day 0
Study: NCT02330471

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spray
Description: surgical method to achieve intraoperative hemostasis by a superficial electrocoagulation of 80 Watt voltage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forced
Description: surgical method to achieve intraoperative hemostasis by a deep tissue electrocoagulation of 80 Watt voltage
Study: NCT03267576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Description: Participants will receive canagliflozin 300 mg oral tablet once-daily for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Description: Participants will receive canagliflozin 300 mg oral tablet once-daily for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Description: Participants will receive sitagliptin 100 mg oral tablet once-daily for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Description: Participants will receive sitagliptin 100 mg oral tablet once-daily for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will receive metformin at a stable dose of \>= 1500 mg/day throughout the study including the washout period between each intervention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will receive metformin at a stable dose of \>= 1500 mg/day throughout the study including the washout period between each intervention.
Study: NCT01247012

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omegaven
Description: Omegaven 1g/kg/day until infant receiving full enteral feeds

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lipid minimization
Description: 1g/kg/day daily until infant receiving full enteral feeds~IF conjugated bili rises above 100, crossover to Omegaven (1gram/kg/day)
Study: NCT03607292

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior sciatic nerve block
Description: A straight line along the femoral catheter was drawn between the anterior superior iliac spine and the finger palpating the pubic bone, the index finger was placed over the femoral artery pulse, a line was drawn perpendicular to the femoral fold. Over the pulse of the femoral artery, a point 4-5 cm lateral. The sciatic nerve was imaged by USG along the needle route and the needle was advanced to the nerve.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior sciatic nerve block
Description: Patient was positioned laterally, with the limb to be blocked uppermost. The lower leg was straight extended and the upper extremity was bent 90° from the knee and was directed forward on the lower straight extended extremity. The patient's greater trochanter and posterior superior iliac spine were palpated and joined with a line, and a line was drawn 4 cm above the first line perpendicular to the caudal line. The USG probe was placed between the greater trochanter and the coccyx at the entry point of the needle and the needle was advanced by imaging the nerve.
Study: NCT00542425

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: teriparatide
Description: teriparatide 20 µg subcutaneous daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous daily
Study: NCT02901249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Study: NCT05466084

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tissue Glue for mesh fixation
Description: one arm of the study had their mesh fixed with tissue glue applied at multiple sites

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metallic Tackers for mesh fixation
Description: in the other arm mesh was fixed with tackers applied avoiding the triangle of pain and the triangle of doom using a three point fixation technique; Cooper's ligament, medial cranial edge of the mesh and just lateral to the inferior epigastric vessels.
Study: NCT03770741

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modify cardio-respiratory support to avoid cerebral hypoxia
Description: modification of cardio-respiratory support based on an evidence-based treatment guideline

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Monitoring and treatment according to local guidelines and practice
Study: NCT01631487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39439335 10 mg
Description: Multiple (once daily for 21 days) oral doses of JNJ-39439335 10 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39439335 10 mg
Description: Multiple (once daily for 21 days) oral doses of JNJ-39439335 10 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39439335 10 mg
Description: Multiple (once daily for 21 days) oral doses of JNJ-39439335 10 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39439335 25 mg
Description: Multiple (once daily for 21 days) oral doses of JNJ-39439335 25 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39439335 25 mg
Description: Multiple (once daily for 21 days) oral doses of JNJ-39439335 25 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39439335 25 mg
Description: Multiple (once daily for 21 days) oral doses of JNJ-39439335 25 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39439335 50 mg
Description: Multiple (once daily for 21 days) oral doses of JNJ-39439335 50 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39439335 50 mg
Description: Multiple (once daily for 21 days) oral doses of JNJ-39439335 50 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39439335 50 mg
Description: Multiple (once daily for 21 days) oral doses of JNJ-39439335 50 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple (once daily for 21 days) oral doses of matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple (once daily for 21 days) oral doses of matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple (once daily for 21 days) oral doses of matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple (once daily for 21 days) oral doses of matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple (once daily for 21 days) oral doses of matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple (once daily for 21 days) oral doses of matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple (once daily for 21 days) oral doses of matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple (once daily for 21 days) oral doses of matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple (once daily for 21 days) oral doses of matching placebo.
Study: NCT02368093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan hydrobromide
Description: 120mg per day with once daily dose taken after breakfast for 6 months
Study: NCT01846962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: The administered dose of topical steroid was 400mcg or 800mcg/day (\<150 cm or \>150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone
Description: The administered dose of topical steroid was 440mcg or 880mcg/day (\<150 cm or \>150 cm). Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: six-foods elimination diet
Description: six-foods elimination diet. The standard panel of foods tested included the 6 most common allergenic foods in childhood (cow's milk, egg, soy, wheat, peanuts, fish), plus foods that were suspiciously implicated in triggering an allergic reaction referred by patients or their parents. Both perennial (dust mite, Parietaria, Alternaria, cat and dog dander) and seasonal (grass pollen including Graminaceae, Olea europea, Platanus) aeroallergens have been tested.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Viscous Budesonide (OVB)
Description: The administered dose of topical steroid was 1mg/day or 2mg/day (\<150 cm or \>150 cm). Patients were trained to prepare a homemade suspension of OVB prepared by mixing inhaled budesonide with viscous solutions of sodium alginate and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
Study: NCT04393597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1458 (fasted)
Description: Subjects take single dose of DWJ1458 on a fated condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1458 (fasted)
Description: Subjects take single dose of DWJ1458 on a fated condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1458 (fed)
Description: Subjects take single dose of DWJ1458 after high-fat diet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1458 (fed)
Description: Subjects take single dose of DWJ1458 after high-fat diet
Study: NCT00913887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium 75 mg Tablets Under Fasting Conditions (Geneva Pharmaceutical)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Sodium 75 mg Tablets Under Fed Conditions (Geneva Pharmaceutical)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voltaren 75 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)
Study: NCT02443246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 B.O.N. Injection (cholecalciferol 200,000IU)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 B.O.N. Injection (cholecalciferol 200,000IU)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00361231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
Study: NCT01668446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: sildenafil tablets(50 mg) daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: sildenafil tablets(50 mg) daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol valerat
Study: NCT03158740

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DII-Based Counseling System
Description: DII-Based Counseling System, including 12 weekly classes in reducing inflammation by adopting dietary patterns low in inflammation and also through physical activity and stress reduction. Participants will also have access to our Imagine Healthy Online Portal. Group-based behavior change programs provide a way for members to share successes and obtain and provide support to one another.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: general health education control
Description: The standard of care arm will receive general health information (e.g., general guidelines of healthy eating and physical activity, stress management, cancer screening, etc.). This information will be provided through email, which will include a weekly newsletter, healthy recipes that are not focused on reducing the DII scores, links to online content, and health-related event announcements in and around Columbia, SC. Any participants in the standard of care arm who does not use email regularly may request for items to be mailed to their mailing address.
Study: NCT03580278

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABY-035/AFO2
Description: Analyze the safety, tolerability, PK, and efficacy of ABY-035/AFO2 that 25 subjects will receive for treatment of their active plaque psoriasis

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABY-035/AFO2
Description: Analyze the safety, tolerability, PK, and efficacy of ABY-035/AFO2 that 25 subjects will receive for treatment of their active plaque psoriasis
Study: NCT03082911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone call
Description: A brief telephone intervention at the same time of sending the invitation letter plus the habitual invitation process used in the screening program (described in control group). Each phone call will last approximately 5 minutes.~Calls will be made by the administrative staff of the Screening Technical Office, which is experienced in telephone attention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Invitation letter
Description: The habitual invitation strategy used in the screening program . Three letters are send by post: 1- An invitation letter plus an information leaflet and a list of pharmacies in which people can obtain the screening test. 2- A reminder letter for those who have not participated after 5 weeks of sending the first letter. 3- A second reminder letter for those who have collected the kit in the pharmacy but have not returned it with the sample

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Invitation letter
Description: The habitual invitation strategy used in the screening program . Three letters are send by post: 1- An invitation letter plus an information leaflet and a list of pharmacies in which people can obtain the screening test. 2- A reminder letter for those who have not participated after 5 weeks of sending the first letter. 3- A second reminder letter for those who have collected the kit in the pharmacy but have not returned it with the sample
Study: NCT02425956

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GE Optima/Discovery® MRI data of the liver
Description: GE Optima 1.5T®/Discovery 3.0T® MRI data scanning data of the liver and surrounding tissues will be acquired using both field strengths for GE IDEAL IQ® and single field strength with FerriScan® (Resondence Health) Specialized Reconstruction Service, according instructions provided by manufacturer
Study: NCT04154293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Topical Isotretinoin ointment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: Topical Isotretinoin ointment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical Vehicle Ointment
Study: NCT05734911

Intervention type: DRUG
Intervention: Niraparib
Description: We did not set a fixed starting dose and strict medication standard,compared with a randomized controlled trial.In our study,enrolled patients received different oral doses of niraparib until disease progression, severe toxicity occurred, or death in reality. We were interested in the dose adjustment and duration of niraparib in real world.
Study: NCT02455336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Fenofibrate is a peroxisome proliferator-activated receptor alpha agonist that is demonstrated to reduce triglyceride concentrations in the blood.

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: A cohort of participants will be randomized to receive no study drug, but will engage in study encounters.
Study: NCT02177331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacidipine
Study: NCT01656005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Dose titration: 3.125mg bid for 1 week, 6.25mg bid for 1 week, 12.5mg bid for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol
Description: Dose titration: 1.25mg od for 1 week, 2.5mg od for 1 week, 5mg for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclometasone/formoterol
Description: 2 puffs bid for first 5 weeks in each treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclometasone/formoterol
Description: 2 puffs bid for first 5 weeks in each treatment arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: 1 puff daily for first 4 weeks of each treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: 1 puff daily for first 4 weeks of each treatment arm
Study: NCT06507891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-A3334 tablets
Description: TQ-A3334 is a highly efficient and highly selective Toll-like receptor-7 (TLR-7) agonist. TLR-7 can induce the release of a series of pro-inflammatory cytokines, including interferon alpha (IFN-α), Interleukin 12 (IL-12), Tumor Necrosis Factor Alpha (TNF-α), and promote the maturation and antigen presentation of dendritic cells, play an antitumor effect.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-A3334 tablets + Anlotinib capsules
Description: TQ-A3334 is a highly efficient and highly selective TLR-7 agonist. TLR-7 can induce the release of a series of pro-inflammatory cytokines, including IFN-α (interferon-α), IL-12 (Interleukin 12), TNF-α, and promote the maturation and antigen presentation of dendritic cells, play an antitumor effect.~Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor.
Study: NCT02790528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 20mg QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug will be administered.
Study: NCT00109798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Patient will take drug on day 1-5 of 28 day schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Patient will have IV on days 2-6 on a 28-day schedule
Study: NCT02888886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires about food habits and tobacco

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spirometry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carotid echography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: for genetic polymorphism analysis, CRP, homocysteine and cytokine tests, glycemia and dyslipidemia analyses